Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma. The pharmaceutical…
News
After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National Institute for Health and Care…
NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple…
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem Therapeutics‘ cell-based therapy for the…
A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against…
The National Cancer Institute (NCI) has awarded $1.7 million to support the work of a University of Arkansas for Medical…
Stand Up To Cancer (SU2C) has awarded the 2020 SU2C Sharp Tank Award to Catherine Marinac, PhD, to support her research examining how…
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
A nonprofit–industry partnership, led by RCSI University of Medicine and Health Sciences of Dublin and SkylineDx, aims to advance genetic testing to better guide doctors…
The navigation platform HealthTree has added a feature that enables people with myeloma to communicate with other patients on specific disease topics. Called Myeloma Crowd…
